Nayan Acharya

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder
    Nayan Acharya
    Eli Lilly Research Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:587-94. 2006
  2. ncbi request reprint Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD
    John Polzer
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 61:713-9. 2007
  3. doi request reprint Answers to the most common questions about the hepatic safety profile of duloxetine
    Madelaine M Wohlreich
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Postgrad Med 120:111-8. 2008
  4. ncbi request reprint Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Drug Saf 3:143-53. 2008
  5. ncbi request reprint Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources
    Indiana Strombom
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Drug Saf 3:154-62. 2008
  6. doi request reprint Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
  7. doi request reprint Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials
    Jerry A Hall
    Abbott Laboratories, Indianapolis, USA
    Expert Opin Drug Saf 9:525-37. 2010
  8. doi request reprint Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Indianapolis, Indiana 46285 6156, USA
    J Child Adolesc Psychopharmacol 22:157-65. 2012
  9. ncbi request reprint Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials
    Charles M Beasley
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    J Clin Psychopharmacol 27:682-6. 2007

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder
    Nayan Acharya
    Eli Lilly Research Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:587-94. 2006
    ..Uncertainty regarding relationships of antidepressant treatment and suicidality encouraged systematic review of data on suicidal behaviors and ideation from Phase II and III clinical trials of duloxetine for major depressive disorder (MDD)...
  2. ncbi request reprint Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD
    John Polzer
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 61:713-9. 2007
    ..We systematically examined potential aggression/hostility-related events in a meta-analysis of acute clinical trials of atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  3. doi request reprint Answers to the most common questions about the hepatic safety profile of duloxetine
    Madelaine M Wohlreich
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Postgrad Med 120:111-8. 2008
    ..Therefore, it does not warrant hepatic enzyme monitoring. As with any medication, physicians should follow prescribing guidelines and educate patients on the risks and benefits of duloxetine...
  4. ncbi request reprint Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events
    Joachim Wernicke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Drug Saf 3:143-53. 2008
    ..Review spontaneous reports and epidemiology of hepatic events associated with duloxetine...
  5. ncbi request reprint Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources
    Indiana Strombom
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Drug Saf 3:154-62. 2008
    ..Present results from two hepatic safety studies conducted within 20 months after duloxetine launch...
  6. doi request reprint Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
    ..The present work examined suicide-related events in acute, double-blind, and placebo- or active comparator-controlled trials with atomoxetine...
  7. doi request reprint Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials
    Jerry A Hall
    Abbott Laboratories, Indianapolis, USA
    Expert Opin Drug Saf 9:525-37. 2010
    ..Summarize safety and tolerability of duloxetine in treating diabetic peripheral neuropathic pain...
  8. doi request reprint Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine
    Ludmila A Kryzhanovskaya
    Lilly Research Laboratories, Indianapolis, Indiana 46285 6156, USA
    J Child Adolesc Psychopharmacol 22:157-65. 2012
    ..The purpose of these analyses was to compare the weight and other metabolic changes between adolescents and adults during long-term (at least 24 weeks) olanzapine treatment...
  9. ncbi request reprint Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials
    Charles M Beasley
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    J Clin Psychopharmacol 27:682-6. 2007
    ..05 vs placebo). Data sources were differentially sensitive in detecting changes in suicidal ideation and behaviors. Fluoxetine treatment led to greater benefit rather than risk for suicidality...